ATC Group: A02BC03 Lansoprazole

Anatomical Therapeutic Chemical Classification System

Hierarchical position in ATC classification

Level
Code
Title
1
Alimentary tract and metabolism
2
Drugs for acid related disorders
3
DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)
4
Proton pump inhibitors
5
A02BC03
Lansoprazole

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Route
Amount
ORAL - Oral
30 mg

Active ingredients

Active Ingredient
Description

Lansoprazole is a gastric proton pump inhibitor. It inhibits the final stage of gastric acid formation by inhibiting the activity of H+/K+ ATPase of the parietal cells in the stomach. The inhibition is dose-dependent and reversible, and the effect applies to both basal and stimulated secretion of gastric acid.

Medicines in this ATC group

Drug
Countries

Austria Germany

South Africa

Ecuador

Tunisia

Ecuador

Hong Kong

South Africa

Ecuador

Lithuania

Hong Kong

South Africa

Brazil

Ireland New Zealand Spain

Australia

France Tunisia

Estonia Lithuania

Estonia Lithuania Poland

Singapore

Ecuador Spain

France

Brazil

Tunisia

Canada Singapore United States

Netherlands

South Africa

Hong Kong New Zealand

Hong Kong

Finland

Ireland

Australia

New Zealand

Australia Estonia Ireland Italy United Kingdom ...

Related product monographs

Title
Type
Country
Summary of Product Characteristics (SPC)
UK
Structured Product Labeling (SPL/PLR)
US
Summary of Product Characteristics (SPC)
UK